The Yale IRB approval is a positive catalyst for trial enrollment velocity but does not provide efficacy data. Monitor for Part B/C data readouts and any financing needs given the $2M market cap. The cross-filing context amplifies this as an activist-context and offering-context filing, suggesting potential capital markets activity ahead.
Price Chart
Executive Summary
Clearmind Medicine announced Yale IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II trial of CMND-100 for Alcohol Use Disorder, following positive safety results from Part A. This expands the multi-site study to include Yale alongside Johns Hopkins and Israeli medical centers, accelerating enrollment. The filing is a clinical milestone for a pre-revenue biotech with a $2M market cap, but no financial data or efficacy data is provided.
Key Facts
- Yale University IRB approved patient recruitment for Parts B and C of the CMND-100 Phase I/II trial.
- Part A completed with all 24 participants across four dose cohorts; primary safety and tolerability endpoint met with no serious adverse events.
- Trial sites now include Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- CMND-100 is a non-hallucinogenic, MEAI-based candidate for Alcohol Use Disorder.
Financial Impact
No financial data in filing; pre-revenue clinical-stage biotech with $2M market cap.
Risk Factors
- No efficacy data yet; Phase I/II trial still early-stage.
- Pre-revenue company with $2M market cap faces significant financing risk.
- Forward-looking statements only; clinical timelines may slip.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-097845 |
| Document: ea030483001ex99-1.htm | 0001213900-26-097845 |
| Document: 0001213900-26-097845-index-headers.html | 0001213900-26-097845 |
| Document: 0001213900-26-097845-index.html | 0001213900-26-097845 |
| Document: 0001213900-26-097845.txt | 0001213900-26-097845 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers